Cogent Biosciences Inc
Cogent Biosciences Inc (COGT) Historical Volatility
COGT's 30 day historical volatility is 58.28%, in the 90th percentile of readings over the past year. This is a high percentile, meaning Cogent Biosciences Inc shares have swung far more than usual. COGT's 30 day implied volatility sits at 95.22%, with an IV Rank of 84.52%, leaving IV 36.94 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 18, 2026.
Read more
Tracking COGT historical volatility helps you see how much Cogent Biosciences Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, COGT's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor COGT 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. COGT's 30 day historical volatility, or COGT HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing COGT's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc.
Historical Volatility
Historical movement is elevated versus the past year. The stock has been unusually active.
As of Nov 18, 2026
As of Nov 18, 2026
As of Nov 18, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →